Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 421-426

  Pettit, Robin K ^a   Repp, Kimberly K ^a   Hazen, Kevin C ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Biofilm; Cryptococcus neoformans; XTT susceptibility

Indexed keywords

2,3 BIS(2 METHOXY 4 NITRO 5 SULFOPHENYL) 2H TETRAZOLIUM 5 CARBOXANILIDE; AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; NYSTATIN; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGUS GROWTH; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVITY;

FILOBASIDIELLA NEOFORMANS;

EID: 76649121525     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903136879     Document Type: Article

References (36)

1. Casadevall A, Perfect JR. C ryptococcus neoformans. Washington DC : ASM, 1998.
2. Ma H, May RC. Virulence in Cryptococcus species. A dv Appl Microbiol 2009; 67: 131-190.
3. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans . Clin Microbiol Rev 1995; 8: 515-548 .
4. Alspaugh JA, Perfect JR, Heitman J. Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans . Fung Genet Biol 1998; 25: 1-14 .
5. Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans . PLoS Biol 2006; 4: e410 .
6. Jacobson ES, Emery HS. Temperature regulation of the cryptococcal phenoloxidase. J Med Vet Mycol 1991; 29: 121-124 .
7. Kuhn LR. Effect of elevated body temperatures on cryptococcosis in mice. Proc Soc Exp Biol Med 1949; 71: 341-343 .
8. Steen BR, Lian T, Zuyderduyn S, et al. Temperature-regulated transcription in the pathogenic fungus Cryptococcus neoformans . Genome Res 2002; 12: 1386-1400 .
9. Kraus PR, Boily MJ, Giles SS, et al. Identification of C ryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Euk Cell 2004; 3: 1249-1260 .
10. Silva LKR, Staats CC, Goulart LS, et al. Identification of novel temperature- regulated genes in the human pathogen Cryptococcus neoformans using representational difference analysis. Res Microbiol. 2008; 159: 221-229 .
11. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M. Ventriculoatrial shunt infection due to Cryptococcus neoformans : an ultrastructural and quantitative microbiological study. Neurosurg. 1986; 18: 373-375 .
12. Bauters TGM, Swinne D, Stove V, Nelis HJ. Detection of single cells of Cryptococcus neoformans in clinical samples by solid-phase cytometry. J Clin Microbiol 2003; 41: 1736-1737 .
13. Chandra J, Kuhn DM, Mukherjee PK, e t al. Biofilm formation by the fungal pathogen Candida albicans : Development, architecture, and drug resistance. J Bacteriol. 2001; 183: 5385-5394 .
14. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science. 1999; 284: 1318-1322 .
15. Hawser SP, Douglas LJ. Resistance of C andida albicans biofilms to antifungal agents in vitro . Antimicrob Agents Chemother 1995; 39: 2128-2131 .
16. Repp KK, Menor SA, Pettit RK. Microplate Alamar blue assay for susceptibility testing of Candida albicans biofilms. Med Mycol 2007; 45: 603-607 .
17. Martinez LR, Casadevall A. Susceptibility of C ryptococcus neoformans biofilms to antifungal agents in vitro . Antimicrob Agents Chemother 2006; 50: 1021-1033 .
18. Di Bonaventura G, Pompilio A, Picciani C, et al. Biofilm formation by the emerging fungal pathogen Trichosporon asahii : Development, architecture, and antifungal resistance. Antimicrob Agents Chemother. 2006; 50: 3269-3276 .
19. Doering TL. A unique 1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans . J Bact 1999; 181: 5482-5488 .
20. Chung S, Mondon P, Chang YC, Kwon-Chung KJ. C ryptococcus neoformans with a mutation in the tetratricopeptide repeat-containing gene, CCN1, causes subcutaneous lesions but fails to cause systemic infection. Infect Immun. 2003; 71: 1988-1994 .
21. Clinical Laboratory Standards Institute. M ethod for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A2 2nd edn. Wayne, PA : Clinical Laboratory Standards Institute, 2002 .
22. Jacobson E S, Tingler MJ. Strains of Cryprococcus neoformans with defined capsular phenotypes. J Vet Mycol 1994; 32: 401-404.
23. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15: 535-537 .
24. Carrillo-Munoz AJ, Quindos G, Tur C, et al. I n vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44: 397-401 .
25. Jin Y, Yip HK, Samaranayake H, Yau JY, Samaranayake LP. Biofilmforming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 2003; 41: 2961-2967 .
26. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888 .
27. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002; 46: 1773-1780 .
28. Ramage G, VandeWalle K, Bachman SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. J Antimicrob Chemother 2002; 46: 3634-3636 .
29. Ramage G, VandeWalle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001; 45: 2475-2479.
30. Zaragoza O, Frases S, Casadevall A. Pathogenicity of C ryptococcus neoformans : an evolutionary perspective. In: Baquerro F, Nombela C, Cassell GH, Gutierrez JA (eds). Evolutionary Biology of Bacterial and Fungal Pathogens Washington, DC: ASM Press, 2008; 581-590 .
31. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997-2007: 10.5 year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-123 .
32. Thompson III GR, Wiederhold NP, Fothergill AW, e t al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans . Antimicrob Agents Chemother 2009; 53: 309-311 .
33. Liu OW, Chun CD, Chow ED, e t al. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans . Cell 2008; 135: 174-188 .
34. Block ER, Jennings AE, Bennett JE. Variables Influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother 1973; 4: 392-395 .
35. Peng T, Galgiani JN. I n vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans , and other pathogenic yeasts. Antimicrob Agents Chemother 1993; 37: 2126-2131 .
36. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun 2005; 73: 6350-6362 .